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Abstract
Background: Although European Borrelia burgdorferi sensu lato isolates have been divided into five
genospecies, specific tools for the serotype characterization of only three genospecies are available.
Monoclonals antibodies (mAbs) H3TS, D6 and I17.3 identify B. burgdorferi sensu stricto (ss.), B.
garinii and B. afzelii respectively, but no mAbs are available to identify B. valaisiana. In the same way,
specific primers exist to amplify the OspA gene of B. burgdorferi ss., B. garinii and B. afzelii. The aim
of the study was to develop species-specific mAb and PCR primers for the phenotypic and genetic
identification of B. valaisiana.
Results: This study describes a mAb that targets OspA of B. valaisiana and primers targeting the
OspA gene of this species. As the monoclonal antibody A116k did not react with strains NE231,
M7, M53 and Frank and no amplification was observed with strains NE231, M7 and M53, the
existence of two subgroups among European B. valaisiana species was confirmed.
Conclusions: The association of both monoclonal antibody A116k and primers Bval 1F and Bval
1R allows to specific identification of the B. valaisiana isolates belonging to subgroup 1.
Background
Lyme borreliosis (LB) caused by a spirochetal species Bor-
relia burgdorferi sensu lato (sl.) is a multisystemic illness
distributed worldwide [1]. In North America and Eurasia,
LB is the most common tick-borne disease [2]. On the
basis of protein profiles, DNA-DNA relatedness and rRNA
gene restriction pattern, B. burgdorferi sl. strains have been
previously divided into three species: B. burgdorferi sensu
stricto (ss.), B. garinii and B. afzelii [3,4]. B. burgdorferi ss.
was found in ticks and patients infected in Europe as well
as in North America, whereas B. garinii and B. afzelii were
only found in ticks and patients infected in Eurasia [4,5].
B. andersonii and B. bissettii were described in North Amer-
ica [6,7], while B. japonica has been defined in Japan [8]
and B. lusitaniae in Portugal [9].
First isolated in Valais-CH, from an I. ricinus tick, VS116
was characterized as B. valaisiana novel species [10]. As
other species, it appeared that its geographical distribu-
tion was not uniform. In Switzerland, Scandinavia and
the Netherlands, B. valaisiana was less frequently isolated
than B. garinii and B. afzelii. In Ireland however, B. valaisi-
ana was described as the most prevalent genospecies [11].
More recently, B. valaisiana has been isolated in Japan and
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East Asia from I. nipponensis, I. columnae and I. granulatus
[12,13].
An association between clinical outcome and infection by
strains of different genospecies has been suggested and
suspicion of a pathogenic potential of B. valaisiana in
humans was described [14,15]. Therefore, genospecies
classification may increase the sensitivity of serologic and
genetic analysis by appropriate choice of target antigens.
Electrophoretic mobility of the major proteins allows us
to distinguish most Borrelia genospecies, but monoclonal
antibodies (mAb) are used to formally identify species on
immunoblots. Up to now, only B. burgdorferi ss., B. garinii
and B. afzelii among European isolates could be character-
ized by mAbs, H3TS was directed against OspA of B burg-
dorferi  ss., D6 directed against a 12 kDa protein of B.
garinii and I17.3 reacted with OspB of B. afzelii [16]; spe-
cific primers GI, GII and GIII were directed against ospA
gene of Borrelia burgdorferi ss,  B. garinii and  B. afzelii,
respectively [17]. In this study, the major outer surface
protein OspA of the reference strain VS116 was selected as
antigen for mAbs production, because of its particular
protein profile in SDS-page and its potential discrimina-
tive utility. In the same way, we have designed primers
specific to ospA gene of B. valaisiana. We described a mAb
and primers specific to the major group of European B.
valaisiana.
Methods
Bacterial strains
The Borrelia burgdorferi sl. strains used in this study are
listed in Table 1 [see Additional file 1].
All Borrelia isolates were grown in MKP medium [30] at
33°C. Extraction of DNA was performed as described pre-
viously [16]. B. burgdorferi sl. isolates were all character-
ized by RFLP of amplicons digested by Mse I (Boehringer,
Mannheim, Germany) and Dra I (Life technology, CH) as
described by Postic [18]. All the Borrelia isolates were sub-
mitted to reactivity of mAb H3TS, I 17.3, D6 and A116k
[16]
B. turicatae, B. parkeri, B. coriaceae, B. anserina were kindly
provided by T. Schwan (Rocky Mount. Lab, Hamilton,
MT, USA). Other bacteria isolates listed on Table 1 were
cultured and characterized by usual laboratory techniques
in our department of bacteriology.
ELISA for screening of hybridoma supernatants
Low-passages, whole-cell of VS215 isolate of B. burgdorferi
ss., VS102 of B. garinii, VS461 of B. afzelii and VS116 of B.
valaisiana were harvested in the log-phase growth, centri-
fuged and the resulting cell pellet was rinsed twice with
PBS (Phosphate-Buffered Saline, pH 7.2, 0.1 M) with
MgCl2 5 mM. The cells were suspended in distilled water.
Concentrations were equally adjusted to 10 µg/ml and the
four antigens were heated 5 min with 5% SDS at 37°C
then 15 min at 95°C. The microwells of the ELISA plates
were coated with the four strains in Na2CO3, 0.1 M, pH
9.6 at 4°C overnight. The wells were washed four times in
PBS-T (PBS with 0.01% Tween) and blocked for 1 hour
with BSA 1% in PBS and again washed four times. Super-
natants of hybridomas were diluted 1/3 in PBS-T. Plates
were incubated at 37°C for 1 hour and then washed four
times with PBS-T. The conjugate (goat anti-mouse polyva-
lent conjugated to alkaline phosphatase (Sigma)) diluted
1/1000 in PBS-T was added and incubated at 37°C for 2
hours. After four washing steps, substrate (para-Nitrophe-
nylphosphate, Virion, Rüschlikon, Switzerland) was
added and plate incubated at room temperature for 15
min. ODs were read by a microplate reader at 405 nm
(with reference OD at 620 nm).
Table 2: Bacteria, other than Borrelia burgdorferi sensu lato, evaluated in this study
Bacterial species Reactivity with mAb A116k PCR with primers to OspA
Borrelia anserina Neg Neg
B. coriaceae Neg Neg
B. hermsii Neg Neg
B. parkeri Neg Neg
B. turicata Neg Neg
Aeromonas hydrophila Neg Neg
Candida albicans Neg Neg
Candida krusei Neg Neg
Escherichia coli Neg Neg
Klebsiella pneumoniae Neg Neg
Pseudomonas aeruginosa Neg Neg
Salmonella enteritidis Neg Neg
Staphyloccocus aureus positive with 70 kDa and 75.3 kDa proteins Neg
Staphyloccocus epidermidis Neg NegBMC Infectious Diseases 2003, 3 http://www.biomedcentral.com/1471-2334/3/14
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Development of B.valaisiana specific monoclonal 
antibodies
The strain VS116 was used to produce mAbs specific to B.
valaisiana. 200 µg of proteins were separated on a 12%
Sodium dodecyl sulfate-polyacrylamide gel electrophore-
sis. Gel was cut into three parts. Both external parts were
stained with Coomassie blue and used as references to cut
the OspA band from the medium part of the gel. The
OspA portion was thereafter used for immunization and
the rest of the gel stained to confirm the extraction of the
selected protein.
The immunization kit of ISL (Readysysteme, Zursach, AG-
CH) was used. An estimated fraction of 20 µg proteins of
a 12% gel containing the OspA band was incubated 48 h
with monolayer of support cells provided with the kit.
One mouse was sacrificed to extract splenocytes. The
splenocytes were incubated four days in immunization
medium with 20 µg of fresh antigen and pre-primed sup-
port cells.
Immunogen splenocyte suspension was then prepared
and mixed with myeloma cells provided with the kit (ratio
1:10 with the splenocytes). The cells were fused with pol-
yethylen glycol in HAT (Hypoxanthine, Aminopterin,
Thymidine) medium and the resultant hybridomas were
seeded into multi-well plates.
Four days later, supernatants were screened for antibody
production by ELISA as described above and specificity of
positive supernatants was then confirmed by using an
immunoblot assay with VS215 (B. burgdorferi ss.), VS102
(B. garinii), VS 461 (B. afzelii) and VS116 (B. valaisiana) as
antigens [15]. The hybridomas which produced specific
mAbs reactive to B. valaisiana were cloned by the limiting
dilution technique.
Subtyping of mAbs was performed by immunoblot with
peroxidase-conjugated rabbit antibodies specific for dif-
ferent isotypes of mouse immunoglobulins (Pierce, Rock-
ford IL, USA)
PCR assay
Based on the comparison of ospA sequences, the following
oligonucleotide primers specific to B. valaisiana were used
in this study : Bval 1F 5'-TGCTGAAAATGCTACAAAAG-
CAGT-3' (forward primer) and Bval 1R 5'-CAA-
GACAAAACTTGTATTTACAAAAC-3' (reverse primer).
Forward and reverse primers are located on the sequence
of the ospA gene of B. valaisiana VS116 isolate at nucle-
otide position 453 to 476 and 696 to 721, respectively.
PCR assays were performed with a Perkin Elmer 9600
thermocycler. Taq DNA polymerase, the four deoxynucle-
otide triphosphates and the reaction buffer were used as
recommended by the supplier (Qiagen, Basel, Switzer-
land). Twenty pmol of each primer were used per 50 µl
reaction mixture. About 100 ng of total genomic DNA was
amplified for 40 cycles under the following conditions :
94°C, 3 min.; 40 cycles (60°C for 1 min, 72°C for 1 min,
94°C for 1 min) 60°C for 1 min, 72°C for 7 min, 4°C.
PCR amplification products were resolved onto 1.0 % aga-
rose electrophoresis gels and visualised under U.V. light
using ethidium bromide. Physical containment measures
warranted the absence of DNA contamination in the PCR
procedure.
Computer analysis, nucleotide sequence and accession 
numbers
Sequence alignments was done with EMMA of the
EMBOSS (European Molecular Biology Open Software
Suite, http://www.hgmp.mrc.ac.uk/Software/EMBOSS/).
EMMA calculates the multiple alignment of nucleic acid
or protein sequences according to the method of Thomp-
son et al [31]. The default parameter values were used.
The ospA sequences have been retrieved from Genbank
with accession numbers Y10837, Y10838, AF095947,
AF095943, Y10841, AF095942, Y10840, X68059,
X85442, X14407, S88693, Y10897, Y10893, Y10892,
X62387, Z29087, Y10896, X85441, Z29086, S48323,
X80256, and X80254 for Borrelia strains PotiB1, PotiB2,
M53, M7, UK, AR-2, VS116, 19857, 297, B31, 25015,
DN127, HO14, IKA2, Pgau, VS461, VS100, WABSou,
G25, Pbi, PBr, and T25, respectively. The ospA sequence of
the Borrelia strain Ip90 has been published [32].
The nucleotide sequence of ospA gene from strain NE231
was determined by the dideoxy chain termination tech-
nique with the "Prism ready reaction dye deoxy-termina-
tor cycle sequencing" kit (Applied Biosystem). The ospA
sequence of NE231 has been entered in the EMBL/Gen-
bank databases with accession number AJ249467.
Results and Discussion
The characterization of B. valaisiana was usually pro-
ceeded by rRNA gene restriction pattern after digestion by
EcoRI and HindIII which contain three and four DNA frag-
ments respectively [10], by RFLP of amplicons resulting
from intergenic spacer of 23S-5S rRNA which contains
four DNA fragments [18] or by hybridization on ampli-
cons of 16s RNA gene [14]. Species specific primers
designed on 16s RNA were described including Borrelia
burgdorferi ss, B. garinii, B. afzelii and B. valaisiana [19]. The
primers we designed in the OspA gene, as well as the mon-
oclonal antibody evaluated here allowed us to specifically
identified the major European group of B. valaisiana, as
previously described as group I [20].
Phenotypic [16,21,22] and genetic [23] analyses of Euro-
pean isolates of B. burgdorferi sl. have demonstrated anti-BMC Infectious Diseases 2003, 3 http://www.biomedcentral.com/1471-2334/3/14
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genic and structural heterogeneities of the OspA protein.
B. burgdorferi ss. as exemplified by VS215 produced two
major proteins at 31 kDa (OspA) and 34 kDa (OspB); B.
garinii,  isolate VS102, produced a single predominant
OspA protein at 33 kDa and B. afzelii as the reference
strain VS461 exhibited two major proteins OspA and
OspB at 32 kDa and 35 kDa, respectively. Although the
isolate VS116, B. valaisiana reference strain, had first been
described as a new group, based on the OspA at 33.5 kDa
[21], additional isolates of B. valaisiana showed more var-
iability. The major outer surface membrane protein OspA
of B. valaisiana were therefore in the range of 30 to 36 kDa
[10,12]. Similarly, B. lusitaniae isolates were phenotypi-
cally heterogeneous within species. Such variability pre-
vents a phenotypic characterization of this two species
without specific markers such as mAbs. Although all B.
valaisiana strains presented a dominant protein band of
32 to 34 kDa, none of them showed a reaction with OspA
specific mAbs: H3TS, LA26 and LA31 as already described
[10].
In this study five supernatants screened for antibody pro-
duction by ELISA presented a preferential reactivity to B.
valaisiana. The specificity was nevertheless confirmed on
immunoblot by using total protein extracts from B. burg-
dorferi ss., B. garinii, B. afzelii and B. valaisiana. All the five
mAbs produced were IgA specific to B. valaisiana and
reacted with OspA of this species. Because of its strongest
reaction with VS116 strain of B. valaisiana, A116k mAb
was selected for further characterization.
Sensitivity and specificity of A116k mAb was evaluated on
immunoblot by testing following controls. A116k mAb
did not bind to any protein of the 90 other B. burgdorferi
sl. isolates belonging to B. burgdorferi ss. (n = 25), B. garinii
(n = 25), B. afzelii (n = 25), B. lusitaniae (n = 5), B. japonica
(n = 5), B. andersonii (n = 2) and B. bissettii (n = 3) show-
ing 100% of specificity. Furthermore an immunoblot was
performed with B. turicatae, B. parkeri, B. coriaceae, B. anse-
rina and 12 unrelated bacterial species (Table 1). A116k
mAb did not bind to any of them excepted with two pro-
teins (70 kDa and 75.3 kDa) of Staphylococcus aureus. The
reactions were nevertheless much weaker than with the
OspA of B. valaisiana isolates accounting for highly prob-
able non-specific cross-reaction. Twenty among 24 B. val-
aisiana  isolates had been easily identified with A116k
mAb. However, four isolates (NE231, M7, M53 and
Frank) of B. valaisiana presented no reactivity with A116k
mAb. Therefore, the sensitivity reached 83%. The OspA of
these four strains presented a molecular weight lower than
the reference strain VS116 (Figure 1) [22].
In order to improve the detection of strains belonging to
B. valaisiana species, comparison of ospA gene sequences
from isolates belonging to all known B. burgdorferi sensu
lato species was performed and led us to the identification
of oligonucleotide primers that were able to amplify a 269
bp DNA fragment specific to B. valaisiana. Forward and
reverse primers were located on the sequence of the ospA
gene of B. valaisiana VS116 isolate at nucleotide position
453 to 476 and 696 to 721, respectively.
The detection threshold of this PCR assay was determined
by performing amplification reactions on a controlled
number of cells. A stock sample of B. valaisiana strain
VS116 was serially diluted in phosphate saline buffer. The
number of Borrelia cells (± 2.0 × 107 cells/ml) in the stock
sample was determined by dark-field microscopy, and
aliquots of the dilution were tested for amplification
using these primers. It was found that a template DNA
input corresponding to about 5 spirochetes was sufficient
to detect the expected amplified fragment (data not
shown). No signal was observed when template DNA was
omitted from the amplification reaction.
The specificity of the PCR assay was evaluated on the 90
B. burgdorferi sensu lato strains and 14 unrelated bacterial
species (Table 1 [see Additional file 1] and Table 1), pre-
viously tested by using A116k mAb. Three B. garinii (SO1,
BITS, and VS711) and one B. lusitaniae (BR41) strains
were positive. The specificity was therefore 97 %. None of
the 14 unrelated bacteria showed an amplified product
with these primers. Twenty-one out of the 24 B. valaisiana
strains had an amplified product at the expected size
(Table 1 [see Additional file 1]). The strains NE231, M7
and M53 were not amplified with these primers.
Comparison and alignment of the NE231 OspA deduced
amino acid sequence with those of 28 B. burgdorferi sensu
lato strains was performed. Based on this comparison, the
6 analysed B. valaisiana strains (UK, AR-2, VS116, M53,
M7 and NE231) confirmed the existence of 2 subgroups
(Figure 2). The subgroup I consists of three B. valaisiana
isolates (UK, AR-2 and VS116). The amino acid sequences
of OspA from these isolates were 98.9 % to 99.6 %
homologous (Table 3 [see Additional file 2]). Subgroup II
contains three B. valaisiana isolates (M53, M7 and
NE231). OspA sequences of M7 and M53 were identical.
These two sequences had a homology of 98.5 % (4 amino
acid substitutions) with the OspA sequence of strain
NE231. The average identity of the deduced amino acid
sequences of the OspA proteins between subgroup I and
II was about 69.9 %, and between B. valaisiana and repre-
sentative isolates from other B. burgdorferi sensu lato
species varied from 62.1 % to 75 %. These data were con-
cordant with the two subgroups described by Wang [20],
whose results were based on the OspA protein sequence of
eight B. valaisiana isolates (subgroup I: VS116, M19, M49,
M52, AR-2 and UK-c16; subgroup II: M7 and M53). In
addition, a similar divergence has already been suggestedBMC Infectious Diseases 2003, 3 http://www.biomedcentral.com/1471-2334/3/14
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(top) Protein profiles of B. burgdorferi sensu lato isolates after polyacrylamide gel electrophoresis and Western blot on polyvi- nylidene difluoride membrane stained with Coomassie blue Figure 1
(top) Protein profiles of B. burgdorferi sensu lato isolates after polyacrylamide gel electrophoresis and Western blot on polyvi-
nylidene difluoride membrane stained with Coomassie blue. Lanes 1 to 8 B. valaisiana (VS116, NE231, Frank, UK, M7), B. burg-
dorferi sensu stricto (B31), B. garinii [20047], B. afzelii (VS461). (bottom) Area of the OspA Reactivity with monoclonal antibody 
A116k.
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Dendrogram of B. burgdorferi sensu lato isolates (n = 30) Figure 2
Dendrogram of B. burgdorferi sensu lato isolates (n = 30). The B. valaisiana isolates clustered into 3 separated branches confirm-
ing the results previously published by Wang [20] and Masuzawa [12].
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by Masuzawa [12]. His hypothesis was based on molecu-
lar masses of the OspA and on sequences of the ospA gene
of Asian strain Am501 compared to that of the reference
strain VS116. However, a BLAST alignment of the Am501
OspA deduced amino acid sequence with that of M53
OspA revealed only 68% identities (data not shown).
Taken together, these results could mean that some Asian
B. valaisiana belong to a third group (Figure 2), distinct of
group I (VS116) and group II (M53).
The heterogeneity of B. valaisiana species has been previ-
ously evidenced by several authors and on diverse targets
such as rrf-rrl spacer, rrs, fla and OspC genes but was not
revealed by using standard genotyping methods such as
ribotyping [10], RAPD [24] and RFLP [25]. The heteroge-
neity of the ospA gene sequences was previously reported
within the B. garinii species [17,23,25]. Our data, as well
as those from previous publications [12,20] indicated that
such major ospA  gene differences also occur within
another Borrelia genospecies. The ospA gene encodes an
outer membrane lipoprotein that is differentially
expressed by B. burgdorferi sensu lato in ticks and in mam-
mals [26]. Although the role of the OspA protein is not
fully understood, OspA may be important in the bacte-
rium-host interaction. Studies have indicated that OspA
protein possesses B-cell mitogenic and cytokine-stimula-
tory properties [27,28]. It seems also that OspA may play
a role in the adherence of B. burgdorferi sensu lato to dif-
ferent eucaryotic cells [29]. Taking into account all these
features, the heterogeneity observed within the OspA pro-
tein sequences could be a key factor in tissue specificity or
in the infection of specific hosts.
Conclusion
The existence of two subgroups among European B. valai-
siana species was confirmed, as well as the existence of a
third group of B. valaisiana in Asia, as it has already been
described. The heterogeneity was first observed on protein
profile as the OspA band of NE231, M7, M53 and Frank
presented a molecular weight lower than the reference
strain VS116 [22]. In addition, Wang [20] described the
presence of two subgroups based on the OspA protein
sequence of eight strains. One monoclonal antibody and
PCR primers presented in this study are therefore useful
serologic and genetic tools to classify strains of B. valaisi-
ana group I. The lack of reactivity of strain Frank with
monoclonal antibody A116k was not concordant with the
result of the PCR-amplification of ospA gene. Therefore,
further analyses have to be done. The sequence analysis of
the complete OspA  gene should explain this
contradiction.
List of abreviations
Borrelia burgdorferi ss:. Borrelia burgdorferi sensu stricto
Borrelia burgdorferi sl.: Borrelia burgdorferi sensu lato
OspA: outer surface protein A
MAb: monoclonal antibody
PBS: phosphate buffer saline
RFLP: restriction fragment length polymorphism
RAPD: randomly amplified polymorphic DNA
kDa: kilo-Dalton
SDS: Sodium-dodecyl-sulfate
HAT: Hypoxanthine, Aminopterin, Thymidine
OL: our laboratory
Competing interests
None declared.
Authors'contributions
Karine Ryffel has performed all the experimental parts of
the study and wrote the first draft of the manuscript.
Eric Dayer has helped in preparing and advising for the
monoclonal antibody production
Anne-Gabrielle Bretz has cultured and prepared all the
Borrelia isolates used in the study
Edmond Godfroid has designed the primers used for PCR,
performed with his team the sequencing of the OspA
genes
Olivier Péter, I has designed the whole study on Borrelia
valaisiana, advising for the serological analysis (ELISA and
Immunoblots), have writen the intermediate and final
drafts of the manuscript.
Acknowledgments
This research was supported by the Swiss National Science
Foundation (No 32-52739.97), the Valais Foundation for
applied research in Valais hospital medicine. This work is
part of the PhD dissertation of Karine Ryffel.BMC Infectious Diseases 2003, 3 http://www.biomedcentral.com/1471-2334/3/14
Page 8 of 8
(page number not for citation purposes)
Additional material
References
1. Steere AC: Lyme disease [see comments]. N Engl J Med 1989,
321(9):586-596.
2. Bennett CE: Ticks and Lyme disease.  Adv Parasitol 1995,
36:343-405.
3. Canica MM, Nato F, du Merle L, Mazie JC, Baranton G and Postic D:
Monoclonal antibodies for identification of Borrelia afzelii sp.
nov. associated with late cutaneous manifestations of Lyme
borreliosis. Scand J Infect Dis 1993, 25(4):441-448.
4. Baranton G, Postic D, Saint Girons I, Boerlin P, Piffaretti JC and
Assous M et al.:  Delineation of Borrelia burgdorferi sensu
stricto, Borrelia garinii sp. nov., and group VS461 associated
with Lyme borreliosis. Int J Syst Bacteriol 1992, 42(3):378-383.
5. van Dam AP, Kuiper H, Vos K, Widjojokusumo A, de Jongh BM and
Spanjaard L et al.: Different genospecies of Borrelia burgdorferi
are associated with distinct clinical manifestations of Lyme
borreliosis. Clin Infect Dis 1993, 17(4):708-717.
6. Marconi RT, Liveris D and Schwartz I: Identification of novel
insertion elements, restriction fragment length polymor-
phism patterns, and discontinuous 23S rRNA in Lyme dis-
ease spirochetes: phylogenetic analyses of rRNA genes and
their intergenic spacers in Borrelia japonica sp. nov. and
genomic group 21038 (Borrelia andersonii sp. nov.) isolates. J
Clin Microbiol 1995, 33(9):2427-2434.
7. Postic D, Ras NM, Lane RS, Hendson M and Baranton G: Expanded
diversity among Californian borrelia isolates and description
of Borrelia bissettii sp. nov. (formerly Borrelia group DN127).
J Clin Microbiol 1998, 36(12):3497-3504.
8. Kawabata H, Masuzawa T and Yanagihara Y: Genomic analysis of
Borrelia japonica sp. nov. isolated from Ixodes ovatus in Japan.
Microbiol Immunol 1993, 37(11):843-848.
9. Le Flèche A, Postic D, Girardet K, Péter O and Baranton G: Charac-
terization of Borrelia lusitaniae sp. nov. by 16S ribosomal
DNA sequence analysis. Int J Syst Bacteriol 1997, 47(4):921-925.
10. Wang G, van Dam AP, Le Flèche A, Postic D, Péter O and Baranton
G et al.: Genetic and phenotypic analysis of Borrelia valaisiana
sp. nov. (Borrelia genomic groups VS116 and M19). Int J Syst
Bacteriol 1997, 47(4):926-932.
11. Kirstein F, Rijpkema S, Molkenboer M and Gray JS: The distribution
and prevalence of B. burgdorferi genomospecies in Ixodes rici-
nus ticks in Ireland. Eur J Epidemiol 1997, 13(1):67-72.
12. Masuzawa T, Fukui T, Miyake M, Oh HB, Cho MK and Chang WH et
al.: Determination of members of a Borrelia afzelii-related
group isolated from Ixodes nipponensis in Korea as Borrelia
valaisiana. Int J Syst Bacteriol 1999, 49:1409-1415.
13. Masuzawa T, Takada N, Imai Y and Yanagihara Y: Molecular epide-
miology of Borrelia burgdorferi sensu lato in the East Asia. In
VIII International Conference on Lyme borreliosis and other tick-borne
diseases 1999, Abstr O5:5. June 20–24 1999 Munich
14. Rijpkema SG, Tazelaar DJ, Molkenboer M, Noordhoek GT, Plantinga
G and Schouls LM et al.: Detection of Borrelia afzelii, Borrelia
burgdorferi sensu stricto, Borrelia garinii. Clinical Microbiology
and Infection 1997, 3:109-116.
15. Ryffel K, Péter O, Rutti B, Suard A and Dayer E: Scored antibody
reactivity determined by immunoblotting shows an associa-
tion between clinical manifestations and presence of Borrelia
burgdorferi sensu stricto, B. garinii, B. afzelii, and B. valaisiana
in humans. J Clin Microbiol 1999, 37(12):4086-4092.
16. Bretz AG, Ryffel K, Hutter P, Dayer E and Péter O: Specificities and
Sensitivities of Four Monoclonal Antibodies for Typing of
Borrelia burgdorferi Sensu Lato Isolates. Clin Diagn Lab Immunol
2001, 8(2):376-384.
17. Godfroid E, Ben Messaoud A, Poliszczak A, Lobet Y and Bollen A:
Assignment of Borrelia burgdorferi strains G25 and VS461 to
the Borrelia garinii and Borrelia afzelii genospecies, respec-
tively: a comparison of OspA protein sequences. DNA Seq
1995, 5(4):251-254.
18. Postic D, Assous MV, Grimont PA and Baranton G: Diversity of
Borrelia burgdorferi sensu lato evidenced by restriction frag-
ment length polymorphism of rrf (5S)-rrl (23S) intergenic
spacer amplicons. Int J Syst Bacteriol 1994, 44(4):743-752.
19. Liebisch G, Sohns B and Bautsch W: Detection and typing of Bor-
relia burgdorferi sensu lato in Ixodes ricinus ticks attached to
human skin by PCR. J Clin Microbiol 1998, 36(11):3355-3358.
20. Wang G, van Dam AP and Dankert J: Two distinct ospA genes
among  Borrelia valaisiana strains.  Res Microbiol 2000,
151(5):325-331.
21. Péter O and Bretz AG: Polymorphism of outer surface proteins
of  Borrelia burgdorferi as a tool for classification.  Zentralbl
Bakteriol 1992, 277(1):28-33.
22. Ryffel K and Péter O: From the discovery to clinical implica-
tions: Borrelia valaisiana . J Spiroch Tick-borne Dis 2001, 7:64-72.
23. Wilske B, Preac-Mursic V, Gobel UB, Graf B, Jauris S and Soutschek
E et al.: An OspA serotyping system for Borrelia burgdorferi
based on reactivity with monoclonal antibodies and OspA
sequence analysis. J Clin Microbiol 1993, 31(2):340-350.
24. Wang G, van Dam AP, Spanjaard L and Dankert J: Molecular typing
of Borrelia burgdorferi sensu lato by randomly amplified poly-
morphic DNA fingerprinting analysis.  J Clin Microbiol 1998,
36(3):768-776.
25. Rijpkema SG, Herbes RG, Verbeek-De Kruif N and Schellekens JF:
Detection of four species of Borrelia burgdorferi sensu lato in
Ixodes ricinus ticks collected from roe deer (Capreolus
capreolus) in The Netherlands.  Epidemiol Infect 1996,
117(3):563-566.
26. de Silva AM and Fikrig E: Arthropod- and host-specific gene
expression by Borrelia burgdorferi.  J Clin Invest 1997,
99(3):377-379.
27. Wooten RM, Modur VR, McIntyre TM and Weis JJ: Borrelia burgdor-
feri outer membrane protein A induces nuclear transloca-
tion of nuclear factor-kappa B and inflammatory activation
in human endothelial cells. J Immunol 1996, 157(10):4584-4590.
28. Potter MR, Rittling SR, Denhardt DT, Roper RJ, Weis JH and
Teuscher C et al.: Role of osteopontin in murine Lyme arthritis
and host defense against Borrelia burgdorferi. Infect Immun 2002,
70(3):1372-1381.
29. Pal U, de Silva AM, Montgomery RR, Fish D, Anguita J and Anderson
JF et al.:  Attachment of Borrelia burgdorferi within  Ixodes
scapularis mediated by outer surface protein A. J Clin Invest
2000, 106(4):561-569.
30. Preac-Mursic V, Wilske B and Schierz G: European Borrelia burg-
dorferi  isolated from humans and ticks culture conditions
and antibiotic susceptibility. Zentralbl Bakteriol Mikrobiol Hyg [A]
1986, 263(1–2):112-118.
31. Thompson J, Higgins D and Gibson T: W Clustal: Improving the
sensitivity of progressive multiple sequence alignment
through sequence weighting, position-specific gap penalties
and weight matrix choice.  Nucleic Acids Res 1994,
11(22):4673-4680.
32. Jonsson M, Noppa L, Barbour AG and Bergstrom S: Heterogeneity
of outer membrane proteins in Borrelia burgdorferi : compar-
ison of osp operons of three isolates of different geographic
origins. Infect Immun 1992, 60(5):1845-1853.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2334/3/14/prepub
Additional File 1
Table 1 : NAME : A mabPCRTab1.doc (list of Borrelia used in the study)
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2334-3-14-S1.doc]
Additional File 2
Table 3 : NAME : A mabPCRTab3.xls (amino acid identity matrix…)
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2334-3-14-S2.xls]